Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* G6PD deficiency by fluorescent Spot test (for intervention groups and control group receiving DHA-PPQ only (N=50)~* G6PD normal activity by fluorescent Spot test for control groups (N=20)~* Informed consent by participant or caregiver (an assent is required for those 12-17 years)~Exclusion Criteria:~* Enrolled in another clinical trial~* Fever: temperature \>37.5°C (axillary) or history of fever in the last 24 hours~* Evidence of severe illness or active infection other than malaria~* Known allergy to study medications~* Hb \<11 g/dL~* Antimalarials taken within the last 2 weeks~* PQ taken within the last 4 weeks and blood transfusion within the last 90 days~* Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone, nitrofurantoin, nalidixic acid, ciprofloxacin, methylene blue, toluidine blue, phenazopyridine and co-trimoxazole.~* History of severe chronic illness

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- G6PD deficient 0.25 mg/kg PQ + DHAP (Type: EXPERIMENTAL): None
- G6PD deficient 0.4 mg/kg PQ + DHAP (Type: EXPERIMENTAL): None
- G6PD deficient DHAP only (Type: ACTIVE_COMPARATOR): None
- G6PD normal 0.25 mg/kg PQ + DHAP (Type: ACTIVE_COMPARATOR): None
- G6PD normal 0.4 mg/kg PQ + DHAP (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).